Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LIAN LianBio	$0.06 +22.2%	$0.35	$0.27 ▼ $4.99	$34.47M	0.23	1.04 million shs	420,220 shs
PBYI Puma Biotechnology	$3.40 +1.2%	$3.41	$2.23 ▼ $4.13	$166.76M	1.29	412,884 shs	395,407 shs
PROK ProKidney	$3.15 -10.5%	$1.33	$0.46 ▼ $7.13	$1.03B	1.26	3.61 million shs	6.55 million shs
TLSA Tiziana Life Sciences	$1.55 +2.6%	$1.50	$0.63 ▼ $1.91	$176.44M	-0.05	475,669 shs	171,887 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LIAN LianBio	+22.22%	-86.90%	-85.51%	-72.50%	-81.67%
PBYI Puma Biotechnology	-2.33%	-4.55%	-2.04%	+17.48%	-7.95%
PROK ProKidney	-5.63%	-32.05%	+310.30%	+345.06%	+53.04%
TLSA Tiziana Life Sciences	+0.67%	+2.72%	-8.48%	+41.12%	+86.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	4.1359 of 5 stars	3.5	2.0	0.0	0.0	2.0	4.2	3.1
PROK ProKidney	3.4105 of 5 stars	3.2	4.0	0.0	0.0	3.2	3.3	0.6
TLSA Tiziana Life Sciences	1.2384 of 5 stars	0.0	5.0	0.0	0.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LIAN LianBio	0.00	N/A	N/A	N/A
PBYI Puma Biotechnology	3.00	Buy	$7.00	105.88% Upside
PROK ProKidney	2.40	Hold	$6.25	98.41% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LIAN, TLSA, PROK, and PBYI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
PBYI Puma Biotechnology	$230.50M	0.73	$0.86 per share	3.94	$1.88 per share	1.81
PROK ProKidney	$80K	11,525.06	N/A	N/A	($3.41) per share	-0.92
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
PBYI Puma Biotechnology	$30.28M	$0.77	4.42	8.95	N/A	16.37%	49.35%	18.25%	7/30/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest LIAN, TLSA, PROK, and PBYI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	PROK ProKidney	-$0.14	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	PBYI Puma Biotechnology	$0.11	N/A	N/A	N/A	$52.00 million	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LIAN LianBio	N/A	10.06	10.06
PBYI Puma Biotechnology	0.11	1.53	1.43
PROK ProKidney	N/A	10.96	10.96
TLSA Tiziana Life Sciences	N/A	1.02	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LIAN LianBio	74.85%
PBYI Puma Biotechnology	61.29%
PROK ProKidney	51.59%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
LIAN LianBio	7.59%
PBYI Puma Biotechnology	23.30%
PROK ProKidney	41.49%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
PBYI Puma Biotechnology	200	49.63 million	38.07 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable

LIAN, TLSA, PROK, and PBYI Headlines

Recent News About These Companies

Tiziana Life Sciences Ltd (TLSA) - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 2.6% - Here's Why

July 9, 2025 | marketbeat.com

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

June 13, 2025 | seekingalpha.com

Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing

June 13, 2025 | proactiveinvestors.com

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

June 13, 2025 | globenewswire.com

Tiziana Life Sciences to Present at the Bio International Convention

June 13, 2025 | globenewswire.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.comP

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

April 30, 2025 | insidermonkey.com

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts

April 23, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

April 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN, TLSA, PROK, and PBYI Company Descriptions

LianBio NASDAQ:LIAN

$0.06 +0.01 (+22.22%)

As of 07/16/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Puma Biotechnology NASDAQ:PBYI

$3.40 +0.04 (+1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$3.44 +0.04 (+1.03%)

As of 06:11 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

ProKidney NASDAQ:PROK

$3.15 -0.37 (-10.51%)

Closing price 04:00 PM Eastern

Extended Trading

$3.20 +0.04 (+1.43%)

As of 07:59 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tiziana Life Sciences NASDAQ:TLSA

$1.55 +0.04 (+2.65%)

Closing price 04:00 PM Eastern

Extended Trading

$1.49 -0.06 (-3.81%)

As of 07:24 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time